1. Home
  2. TBBK vs SRRK Comparison

TBBK vs SRRK Comparison

Compare TBBK & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBBK
  • SRRK
  • Stock Information
  • Founded
  • TBBK 1999
  • SRRK 2012
  • Country
  • TBBK United States
  • SRRK United States
  • Employees
  • TBBK N/A
  • SRRK N/A
  • Industry
  • TBBK Major Banks
  • SRRK Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • TBBK Finance
  • SRRK Health Care
  • Exchange
  • TBBK Nasdaq
  • SRRK Nasdaq
  • Market Cap
  • TBBK 2.6B
  • SRRK 2.8B
  • IPO Year
  • TBBK 2004
  • SRRK 2018
  • Fundamental
  • Price
  • TBBK $55.17
  • SRRK $26.49
  • Analyst Decision
  • TBBK Buy
  • SRRK Strong Buy
  • Analyst Count
  • TBBK 3
  • SRRK 7
  • Target Price
  • TBBK $55.00
  • SRRK $34.00
  • AVG Volume (30 Days)
  • TBBK 749.3K
  • SRRK 984.5K
  • Earning Date
  • TBBK 10-24-2024
  • SRRK 11-12-2024
  • Dividend Yield
  • TBBK N/A
  • SRRK N/A
  • EPS Growth
  • TBBK 16.50
  • SRRK N/A
  • EPS
  • TBBK 3.95
  • SRRK N/A
  • Revenue
  • TBBK $472,068,000.00
  • SRRK N/A
  • Revenue This Year
  • TBBK N/A
  • SRRK N/A
  • Revenue Next Year
  • TBBK $7.93
  • SRRK N/A
  • P/E Ratio
  • TBBK $13.97
  • SRRK N/A
  • Revenue Growth
  • TBBK 6.73
  • SRRK N/A
  • 52 Week Low
  • TBBK $29.92
  • SRRK $6.76
  • 52 Week High
  • TBBK $59.46
  • SRRK $35.38
  • Technical
  • Relative Strength Index (RSI)
  • TBBK 53.12
  • SRRK 50.87
  • Support Level
  • TBBK $53.16
  • SRRK $25.86
  • Resistance Level
  • TBBK $59.46
  • SRRK $28.11
  • Average True Range (ATR)
  • TBBK 2.20
  • SRRK 1.68
  • MACD
  • TBBK 0.37
  • SRRK -0.92
  • Stochastic Oscillator
  • TBBK 62.73
  • SRRK 11.71

About TBBK The Bancorp Inc

The Bancorp Inc is a financial holding company, through its subsidiary it is engaged in specialty lending namely securities-backed lines of credit, vehicle fleet and another equipment leasing, Small Business Administration lending, insurance policy cash value-backed lines of credit and commercial mortgage-backed loans, generated for sale into commercial mortgage-backed securities markets through securitizations. The company deposits and non-interest income are generated in the payments business which consists of issuing, acquiring, and automated clearing house accounts.

About SRRK Scholar Rock Holding Corporation

Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGFβ1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.

Share on Social Networks: